|
gptkbp:instanceOf
|
gptkb:drug
antiviral drug
|
|
gptkbp:activeIngredient
|
gptkb:voxilaprevir
gptkb:sofosbuvir
velpatasvir
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
J05AP56
|
|
gptkbp:drugInteraction
|
gptkb:rifampin
gptkb:St._John's_wort
gptkb:digoxin
antacids
|
|
gptkbp:form
|
gptkb:tablet
film-coated tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vosevi
|
|
gptkbp:indication
|
chronic hepatitis C infection
patients previously treated with NS5A inhibitor
patients with or without cirrhosis
patients previously treated with sofosbuvir without NS5A inhibitor
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketingAuthorizationHolder
|
gptkb:Gilead_Sciences
|
|
gptkbp:mechanismOfAction
|
gptkb:NS5B_polymerase_inhibitor
NS3/4A protease inhibitor
NS5A inhibitor
|
|
gptkbp:pregnancyCategory
|
B1 (Australia)
N (US)
|
|
gptkbp:prescribes
|
adults
adolescents (12 years and older)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
headache
|
|
gptkbp:usedFor
|
treatment of hepatitis C
|
|
gptkbp:bfsParent
|
gptkb:DB09241
gptkb:velpatasvir_and_voxilaprevir
|
|
gptkbp:bfsLayer
|
7
|